Effect of celecoxib on improving depression: A systematic review and meta-analysis

被引:19
作者
Wang, Zhi [1 ]
Wu, Qiao [2 ]
Wang, Qing [3 ,4 ]
机构
[1] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Tradit Chinese Med & Western Med Dept, Wuhan 430030, Hubei, Peoples R China
[2] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Neurol, Wuhan 430030, Hubei, Peoples R China
[3] Wuhan Univ Sci & Technol, Dept Rehabil Ctr Wuhan Puren Hosp, Wuhan 430080, Hubei, Peoples R China
[4] Wuhan Univ Sci & Technol, Dept Rehabil Ctr Wuhan Puren Hosp, 1 Benxi St, Qingshan Dist, Wuhan 430080, Hubei, Peoples R China
关键词
Celecoxib; Depression; Systematic review; Meta-analysis; Inflammation; TO-MODERATE DEPRESSION; RANDOMIZED DOUBLE-BLIND; BIPOLAR DEPRESSION; MAJOR DEPRESSION; ADJUNCTIVE CELECOXIB; TRIAL; EFFICACY; DISORDER; CANCER;
D O I
10.12998/wjcc.v10.i22.7872
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND Anti-inflammation drugs were uncovered to be a potential therapy for depression. Celecoxib as a selective COX2 inhibitor is also one anti-inflammation drugs. Celecoxib is widely used in the clinic, which is well known by medical workers. It is uncertain whether celecoxib has efficacy in improving depression. AIM To estimate the effect of celecoxib on improving depression. METHODS All literature was searched until 2022. The databases included PubMed, OVID database, Cochrane library, Web of Science, CNKI, Clinicaltrials.gov database and Wanfang database. The random effects model was used to estimate the standardized mean differences with 95%CIs. With determined diagnostic criteria, studies containing patients with depression in the celecoxib group and the control group were included in the meta-analysis. The primary outcome measures were set for depression scale scores. RESULTS Twenty-nine randomized controlled studies were included in the meta-analysis (including 847 subjects with depression and 810 control subjects). The meta-analysis showed that celecoxib had an effect of anti-depression. At the same time, heterogeneity was observed (I-2 = 82.1%, P = 0.00), and meta-regression was implemented to estimate the source of heterogeneity, which showed that the type of depression scale and depression type may lead to the heterogeneity. Subgroup analysis with respect to depression scale and depression type suggested that depression type was the possible main source of heterogeneity. Moreover, Egger's test, Begg's test, funnel plot and Doi plot was implemented, and publication bias was found to be significant. Next, the trim and fill method was used to estimate the influence of publication bias on the outcome of the meta-analysis, which showed that the outcome of the meta-analysis was reliable. Sensitivity analysis was estimated by deleting a study one by one, and the outcome of the meta-analysis was significantly stable. The quality of all randomized controlled trial studies was assessed by risk of bias, which indicated the rank of evidence in the meta-analysis was high. CONCLUSION Celecoxib could be effective for improving depression.
引用
收藏
页码:7872 / 7882
页数:11
相关论文
共 28 条
[1]   Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: Randomized double-blind placebo-controlled study [J].
Abbasi, Seyed-Hesameddin ;
Hosseini, Fahimeh ;
Modabbernia, Amirhossein ;
Ashrafi, Mandana ;
Akhondzadeh, Shahin .
JOURNAL OF AFFECTIVE DISORDERS, 2012, 141 (2-3) :308-314
[2]   CLINICAL TRIAL OF ADJUNCTIVE CELECOXIB TREATMENT IN PATIENTS WITH MAJOR DEPRESSION: A DOUBLE BLIND AND PLACEBO CONTROLLED TRIAL [J].
Akhondzadeh, Shahin ;
Jafari, Sara ;
Raisi, Firoozeh ;
Nasehi, Abbas Ali ;
Ghoreishi, Aboulfazl ;
Salehi, Bahman ;
Mohebbi-Rasa, Soodeh ;
Raznahan, Maedeh ;
Kamalipour, Abbas .
DEPRESSION AND ANXIETY, 2009, 26 (07) :607-611
[3]   Efficacy and safety of celecoxib monotherapy for mild to moderate depression in patients with colorectal cancer: A randomized double-blind, placebo controlled trial [J].
Alamdarsaravi, Maryam ;
Ghajar, Alireza ;
Noorbala, Ahmad-Ali ;
Arbabi, Mohammad ;
Emami, Amirhossein ;
Shahei, Farhad ;
Mirzania, Mehrzad ;
Jafarinia, Morteza ;
Afarideh, Mohsen ;
Akhondzadeh, Shahin .
PSYCHIATRY RESEARCH, 2017, 255 :59-65
[4]   No evidence for clinical efficacy of adjunctive celecoxib with vortioxetine in the treatment of depression: A 6-week double-blind placebo controlled randomized trial [J].
Baune, Bernhard T. ;
Sampson, Emma ;
Louise, Jennie ;
Hori, Hikaru ;
Schubert, K. Oliver ;
Clark, Scott R. ;
Mills, Natalie T. ;
Fourrier, Celia .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2021, 53 :34-46
[5]   Efficacy of Celecoxib Adjunct Treatment on Bipolar Disorder: Systematic Review and Meta-Analysis [J].
Bavaresco, Daniela V. ;
Colonetti, Tamy ;
Grande, Antonio J. ;
Colom, Francesc ;
Valvassori, Samira S. ;
Quevedo, Joao ;
da Rosa, Maria I. .
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2019, 18 (01) :19-28
[6]   The Bidirectional Relationship of Depression and Inflammation: Double Trouble [J].
Beurel, Eleonore ;
Toups, Marisa ;
Nemeroff, Charles B. .
NEURON, 2020, 107 (02) :234-256
[7]  
Cohen B., 2022, StatPearls
[8]   Plasma MCP-1 levels in bipolar depression during cyclooxygenase-2 inhibitor combination treatment [J].
Edberg, David ;
Hoppensteadt, Debra ;
Walborn, Amanda ;
Fareed, Jawed ;
Sinacore, James ;
Halaris, Angelos .
JOURNAL OF PSYCHIATRIC RESEARCH, 2020, 129 :189-197
[9]   Celecoxib: a new augmentation strategy for depressive mood episodes. A systematic review and meta-analysis of randomized placebo-controlled trials [J].
Faridhosseini, Farhad ;
Sadeghi, Ramin ;
Farid, Layla ;
Pourgholami, Meysam .
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2014, 29 (03) :216-223
[10]   Modulation of the inflammatory response benefits treatment-resistant bipolar depression: A randomized clinical trial [J].
Halaris, Angelos ;
Cantos, Adriana ;
Johnson, Katherine ;
Hakimi, Michael ;
Sinacore, James .
JOURNAL OF AFFECTIVE DISORDERS, 2020, 261 :145-152